Steve Sabus compensation by year
Syndax Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2022 |
|---|---|
| Salary | $37,950 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $3,878,100 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $3,916,050 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed April 7, 2023, accession 0000950170-23-012189, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0000950170-23-012189. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 220,000 | — | $25.44 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Syndax Pharmaceuticals Inc's FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Syndax Pharmaceuticals’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Michael Metzger | Chief Executive Officer | $4,113,476 |
| Steve Sabus · this page | Chief Commercial Officer | $3,916,050 |
| Keith Goldan | Chief Financial Officer | $2,992,538 |
| Catherine Madigan | Chief Medical Officer | $2,643,914 |
| Briggs Morrison | President, Head of Research and Development and Former Chief Executive Officer | $2,374,171 |
| Luke Albrecht | General Counsel and Secretary | $1,468,073 |
| Alexander Nolte | Vice President, Chief Accounting Officer and Former Interim Principal Financial Officer | $760,864 |
The full Syndax Pharmaceuticals compensation record
free company briefThis page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Syndax Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.